185 related articles for article (PubMed ID: 15543260)
1. Cholesterol-lowering with statins: are they all the same? - Summary of the Expert Symposium at the 53rd Annual Scientific Sessions of the American College of Cardiology.
International Task Force for the Prevention of Coronary Heart Disease
Timely Top Med Cardiovasc Dis; 2004 Sep; 8():E8. PubMed ID: 15543260
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol-lowering with statins: are they all the same? Summary of the expert symposium at the 53rd Annual Scientific Sessions of the American College of Cardiology.
International Task Force for the Prevention of Coronary Heart Disease
Drugs Today (Barc); 2004 Jun; 40(6):555-61. PubMed ID: 15349133
[TBL] [Abstract][Full Text] [Related]
3. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
4. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
5. [About: pleiotropic effects of statins in atherosclerosis].
Ambrosi P
Arch Mal Coeur Vaiss; 2005 Dec; 98(12):1263; author reply 1263-5. PubMed ID: 16435610
[No Abstract] [Full Text] [Related]
6. [Do the pleiotropic effects of statins have a clinical significance?].
Vergès B
Arch Mal Coeur Vaiss; 2004 Dec; 97(12):1231-5. PubMed ID: 15669365
[TBL] [Abstract][Full Text] [Related]
7. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Mason RP; Walter MF; Day CA; Jacob RF
Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
[TBL] [Abstract][Full Text] [Related]
8. Antioxidative effects of statins.
Adam O; Laufs U
Arch Toxicol; 2008 Dec; 82(12):885-92. PubMed ID: 18670762
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
10. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
Bays HE; Davidson M; Jones MR; Abby SL
Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
[TBL] [Abstract][Full Text] [Related]
11. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
12. [Pleiotropic effects of statins].
Palomäki A
Duodecim; 2004; 120(4):411-8. PubMed ID: 15065459
[No Abstract] [Full Text] [Related]
13. Effects of statins beyond lipid lowering: potential for clinical benefits.
Almuti K; Rimawi R; Spevack D; Ostfeld RJ
Int J Cardiol; 2006 Apr; 109(1):7-15. PubMed ID: 16054715
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy.
Tamargo J; Caballero R; Gómez R; Núñez L; Vaquero M; Delpón E
Pharmacol Ther; 2007 Apr; 114(1):107-26. PubMed ID: 17287023
[TBL] [Abstract][Full Text] [Related]
16. Do statins lower blood pressure?
Mangat S; Agarwal S; Rosendorff C
J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):112-23. PubMed ID: 17562781
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
18. Achieving target cholesterol levels in diabetic patients: potency of the statin or potency of the physician?
Shani M; Dresner J; Vinker S
Isr Med Assoc J; 2008 May; 10(5):354-7. PubMed ID: 18605358
[TBL] [Abstract][Full Text] [Related]
19. The role of statins in reversing atherosclerosis: what the latest regression studies show.
Grines CL
J Interv Cardiol; 2006 Feb; 19(1):3-9. PubMed ID: 16483333
[TBL] [Abstract][Full Text] [Related]
20. [Lowering cholesterol: how low is low enough?].
Czuriga I; Edes I
Orv Hetil; 2006 Jul; 147(29):1349-56. PubMed ID: 16941825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
